INTRODUCTION {#S1}
============

Effective organ function requires both homeostatic maintenance of appropriate cell numbers and injury-induced repair responses that can replace damaged cells, both processes that rely on tissue stem cells. Studies spanning multiple decades have sought to define key molecular regulators of tissue stem cell function; however, the pace at which investigators have been able to interrogate and define such mediators has been constrained by the technological limitations of generating genetically engineered mice and of stem cell transplantation models typically used for such studies. In particular, transgenic and gene knockout-based approaches require the generation and breeding of multiple distinct genetically engineered deletion and/or floxed alleles to disrupt genes of interest in a ubiquitous or tissue-specific manner, and this challenge is exacerbated when the combinatorial effects of perturbing several genes are of interest. Likewise, *ex vivo* genomic manipulation of stem cells requires the isolation and transplantation of these cells, which disturbs key regulatory interactions present in endogenous stem cell niches and can profoundly modify normal stem cell properties ([@R45]). Thus, the field would benefit tremendously from the availability of a programmable, *in vivo* platform to manipulate gene expression in endogenous stem cells without the need to isolate them or to generate complex, multiallelic transgenic animals.

Previous work from our laboratory used a fluorescent reporter system to monitor *in vivo* delivery of DNA encoding Cre recombinase, a sequence-targeted genome-modifying enzyme, to skeletal muscle stem cells (also known as muscle satellite cells) using adeno-associated viruses (AAVs) ([@R41]). In that study, systemic Cre delivery to neonatal mice harboring a *Rosa26*-tdTomato Ai9 reporter allele using AAV serotype 9 (AAV9-Cre) resulted in modification of \~10% of the total satellite cell pool (as indicated by tdTomato fluorescence). Analogous administration of AAV-CRISPR, a system composed of two AAV vectors (one encoding *Staphylococcus aureus* Cas9 \[saCas9\] and a second encoding dual U6-driven guide RNAs targeting sequences flanking the STOP cassette upstream of the Ai9 reporter allele), induced tdTomato fluorescence in 2%--4% of endogenous satellite cells ([@R41]). These results suggest that endogenous muscle satellite cells in neonatal animals are accessible to systemically administered AAVs and can be modified following transduction by these vectors carrying genome-targeting enzymes.

Encouraged by these initial results, we have applied this same tdTomato reporter system in this study to investigate whether systemic AAV administration can also transduce satellite cells in adult animals and whether this approach might be extended to additional AAV serotypes and distinct tissue stem cells and progenitor populations. We report efficient transduction of adult mouse satellite cells following *in vivo* systemic delivery of AAVCre, reaching \>60% of the total satellite cell pool and representing a 6-fold increase over our previous study in neonatal mice ([@R41]). We further reveal that this transduction capacity is not limited to AAV9 but extends to additional AAV serotypes, including AAV8 and Anc80L65 (hereafter designated Anc80). Finally, we report the transduction and genome modification of multiple non-myogenic stem and progenitor cells, including mesenchymal progenitors in the skeletal muscle and dermis, as well as hematopoietic stem and progenitor cells in the bone marrow. Subsequent isolation, differentiation, and transplantation studies confirm that the targeted tissue stem cells retain their regenerative functions following *in situ* AAV transduction and genome modification. Collectively, these studies document efficient *in vivo* genome modification of distinct lineages of stem and progenitor cells across multiple anatomical niches using AAV delivery in adult mammals. This system presents exciting opportunities to pursue *in vivo* gene activation, disruption, and editing strategies in tissue-resident stem cells for therapeutic purposes, as well as approaches to induce or inactivate transgenic or endogenous alleles to uncover novel molecular regulators of stem and progenitor cells within their native niches.

RESULTS {#S2}
=======

We previously demonstrated the feasibility of *in vivo* gene modification in satellite cells by AAV9-mediated delivery of genome-modifying enzymes ([@R41]). As noted earlier, we observed transduction of satellite cells after intraperitoneal delivery of AAV9-Cre in neonatal mice (\~10%) and following intramuscular delivery of AAV9-Cre in adult mice (\~35%). However, we did not evaluate adult satellite cell transduction rates following intravenous injection ([@R41]). Thus, in the current study, we asked whether systemic AAV administration to adult animals might target satellite cells and whether this systemic delivery approach in adults may likewise target other stem cell and progenitor populations in distinct anatomical locations.

To perform this proof-of-concept study, we produced AAV particles encoding Cre recombinase (AAV-Cre) downstream of a cytomegalovirus (CMV) promoter and a chimeric intron packaged with AAV8, AAV9, or Anc80 ([@R50]) and injected them intravenously into young adult (6 weeks old) Ai9 mice (on an *mdx* background: *mdx*;Ai9 mice) ([Figure 1A](#F1){ref-type="fig"}). The Ai9 allele encodes a *Rosa26*-LoxP-STOP-LoxP-tdTomato reporter, which enables irreversible labeling of targeted cells with tdTomato fluorescence, detectable with single-cell resolution, after Cre-mediated excision of the STOP cassette ([@R26]). AAVCre particles were injected intravenously by either the tail vein or the retro-orbital sinus at a low dose (5.5 × 10^11^ to 8 × 10^11^ viralgenomes \[vg\] per mouse) or a high dose (2.2 × 10^12^ vg per mouse). Tissues were then analyzed 2--3 weeks after injection for the presence of tdTomato fluorescence in three well-defined regenerative adult precursor cell populations---skeletal muscle satellite cells, muscle-resident mesenchymal progenitor cells, and bone marrow-localized hematopoietic stem and progenitor cells---all of which are easily identifiable by extensively validated cell surface marker profiles ([@R8]; [@R19]; [@R27]; [@R38]).

We detected tdTomato^+^ muscle satellite cells, defined as CD45^−^ CD11b (Mac-1)^−^ Ter119^−^ Sca-1^--^ β1-integrin^+^ CXCR4^+^ cells ([Figure S1C](#SD1){ref-type="supplementary-material"}) ([@R8]; [@R27]; [@R38]), at frequencies ranging from 8% to 62% in all animals injected with AAV-Cre (n = 24 mice) irrespective of the anatomical location of intravenous injection (retro-orbital or tail vein), indicating robust and reproducible Cre-dependent recombination following *in vivo* transduction of these cells by AAV ([Figures 1B](#F1){ref-type="fig"} and [1C](#F1){ref-type="fig"}). No tdTomato^+^ cells were detected in vehicle-injected controls (n = 6) ([Figures 1B](#F1){ref-type="fig"} and [1C](#F1){ref-type="fig"}). Comparing mice injected with the same serotype of AAV, the percentage of tdTomato^+^ satellite cells roughly correlated with the dose of AAV injected, and on average, more than half of the total pool of satellite cells was transduced and genetically modified with the higher doses of either AAV8-Cre or Anc80-Cre ([Figure 1C](#F1){ref-type="fig"}). We validated these findings by immunofluorescence analysis in a subset (n = 3) of high-dose AAV8-Cre-injected animals, confirming the presence of tdTomato^+^ muscle satellite cells (marked by Pax7 expression and by their localization beneath the basal lamina) ([@R37]) in 29 of 30 of sections analyzed from three AAV-Cre-injected mice ([Figure S1A](#SD1){ref-type="supplementary-material"}). No tdTomato^+^ cells were detected in sections from uninjected controls. Quantification of these microscopy data across all three animals indicated an average \~34% of Pax7^+^ satellite cells that were also tdTomato^+^ ([Figure S1B](#SD1){ref-type="supplementary-material"}), similar to results obtained by flow cytometry ([Figure 1C](#F1){ref-type="fig"}). We observed substantial variability in the frequency of tdTomato^+^ Pax7^+^ muscle satellite cells present in different sections prepared from the same muscle ([Figure S1B](#SD1){ref-type="supplementary-material"}), suggesting that AAV transduction, and subsequent genome modification events, may not be distributed evenly throughout the muscle tissue.

We next investigated whether *in vivo* AAV-transduced and genome-modified satellite cells maintained their myogenic capacity ([Figure 1A](#F1){ref-type="fig"}). Satellite cells sorted from the muscles of AAV-Cre-injected mice retained their ability to proliferate, differentiate, and fuse to form tdTomato^+^ myosin heavy chain (MHC)-expressing myotubes when cultured *ex vivo* ([Figure 2A](#F2){ref-type="fig"}). The relative intensity of the tdTomato signal in fused myotubes appeared to reflect the transduction efficiencies of the sorted populations (as determined by fluorescence-activated cell sorting \[FACS\]), with more highly transduced populations generating visibly brighter tdTomato^+^ myotubes ([Figure 2A](#F2){ref-type="fig"}). Consistent with the unperturbed proliferation and differentiation properties of AAV-Cre-transduced tdTomato^+^ satellite cells, relative quantification of myogenic gene expression indicated equivalent levels of *Pax7*, *Myf5*, and *Myog* expression, with a slight (\~25%) reduction in *Myod1* in tdTomato^+^ satellite cells compared to tdTomato^--^ satellite cells ([Figure S1D](#SD1){ref-type="supplementary-material"}). Finally, we confirmed that AAV-transduced muscle satellite cells retain their myogenic stem cell properties using stringent *in vivo* transplantation assays. tdTomato^+^ satellite cells preserved their capacity to engraft, generate tdTomato^+^ muscle fibers ([Figure 2C](#F2){ref-type="fig"}), and replenish the pool of sublaminar Pax7^+^ satellite cells ([Figure 2B](#F2){ref-type="fig"}) following isolation and transplantation into preinjured recipient muscle. Collectively, these results confirm retention of key myogenic features and satellite cell functions after *in vivo* AAV transduction of muscle satellite cells in adult animals.

In addition to the satellite cell compartment, we detected tdTomato^+^ cells in a subset (ranging from 8% to 46%) of muscle-resident Sca-1^+^ mesenchymal progenitors, which can differentiate to form adipocytes ([Figures S1C](#SD1){ref-type="supplementary-material"}, [S1F](#SD1){ref-type="supplementary-material"}, and [S1G](#SD1){ref-type="supplementary-material"}) ([@R16]; [@R36]; [@R38]; [@R42]), and a subset (ranging from 4% to 33%) of muscle-infiltrating hematopoietic cells (marked by CD45, Mac-1, and/or Ter119) within the muscles of animals injected with different serotypes of AAVCre ([Figures S1C](#SD1){ref-type="supplementary-material"} and [S1E](#SD1){ref-type="supplementary-material"}). A separate experiment evaluating systemic administration of AAV6, AAV8, or AAV9 encoding Cre recombinase under the control of the CMV promoter similarly showed transduction of muscle satellite cells (ranging from 6% to 13%) and muscle-localized Sca-1^+^ progenitors (ranging from 5% to 6%), emphasizing the reproducibility of this *in vivo* delivery system ([Table S1](#SD1){ref-type="supplementary-material"}).

Finally, we assessed local delivery methods to target muscle progenitors using AAV-Cre. For these studies, we used *mdx*;Ai9 animals carrying a *Pax7-ZsGreen* allele to transgenically mark muscle satellite cells ([Figure S2A](#SD1){ref-type="supplementary-material"}) ([@R3]; [@R6]; [@R27]). We delivered 6 3 × 10^11^ vg/mouse of AAV-Cre using serotypes 1, 8, or 9 via direct intramuscular injection, and similar to our results with systemic delivery, analysis of skeletal muscles 3 weeks after local injection of AAV-Cre revealed tdTomato expression in a substantial fraction of hematopoietic lineage cells (ranging from 33% to 62%) ([Figure S2B](#SD1){ref-type="supplementary-material"}), Sca-1^+^ mesenchymal progenitors (ranging from 62% to 80%) ([Figure S2C](#SD1){ref-type="supplementary-material"}), and satellite cells (ranging from 10% to 23%) ([Figure S2D](#SD1){ref-type="supplementary-material"}). Although this genetic approach to mark muscle satellite cells using a *Pax7* reporter allele in *mdx* muscle has been applied previously by our group and others ([@R14]; [@R41]), we cannot rule out that the *Pax7*-*ZsGreen* allele may also mark some myoblast cells in the *mdx* mouse. Nonetheless, together with the results obtained following systemic AAV delivery, these data demonstrate efficient, dose-dependent, and reproducible transduction and delivery of a genome-modifying enzyme by multiple AAV serotypes into skeletal muscle satellite cells and mesenchymal progenitors within their native niche.

To determine whether additional stem cell populations in other anatomical niches might be similarly targeted by systemic AAV administration, we analyzed bone marrow cells harvested from mice injected intravenously with AAV8, AAV9, or Anc80 encoding Cre recombinase ([Figure 3A](#F3){ref-type="fig"}). We observed detectable tdTomato expression within immunophenotypically identified hematopoietic stem cells (HSCs; defined as Lin^−^Sca-1^+^c-kit^+^CD48^−^CD150^+^) (ranging from 3% to 38%) ([Figures 3B](#F3){ref-type="fig"} and [3C](#F3){ref-type="fig"}). These results were reproducible using intravenous delivery through either the tail vein or the retro-orbital sinus ([Figure 3C](#F3){ref-type="fig"}) and in a separate experiment in which we injected CMV-driven Cre using AAV6, AAV8, or AAV9-Cre ([Table S1](#SD1){ref-type="supplementary-material"}). Similar to our results with skeletal muscle satellite cells, bone marrow HSCs were transduced and modified by multiple AAV serotypes with efficiencies that roughly correlated with viral titer ([Figure 3C](#F3){ref-type="fig"}).

In addition to HSCs, we investigated the targeting of more committed hematopoietic precursors in the bone marrow by systemically delivered AAV-Cre. tdTomato fluorescence was detected in multiple subsets of bone marrow progenitors, including common myeloid progenitors (CMPs) (Lin^−^Sca-1^−^c-Kit^+^CD34^+^FcγR^low^, ranging from 4% to 26%), granulocyte monocyte progenitors (GMPs) (Lin^−^Sca-1^−^c-Kit^+^CD34^+^FcγR^+^, ranging from 5% to 17%), and megakaryocyte erythroid progenitors (MEPs) (Lin^−^Sca-1^−^c-Kit^+^CD34^−^FcγR^−^, ranging from 2.5% to 12%) ([Figures S3B](#SD1){ref-type="supplementary-material"} and [S3F](#SD1){ref-type="supplementary-material"}--[S3H](#SD1){ref-type="supplementary-material"}). tdTomato^+^ cells were also detected among lineage-committed erythroid precursors, including EryA cells (basophilic erythroblasts) (Ter119^+^CD71^+^FSC^high^, ranging from 23% to 74%), EryB cells (late basophilic and polychromatic erythroblasts) (Ter119^+^CD71^+^FSC^low^, ranging from 9% to 20%), and a small fraction of EryC cells (orthochromatic erythroblasts and reticulocytes) (Ter119^+^CD71^−^FSC^low^, ranging from 0.8% to 2.5%) ([Figures S3A](#SD1){ref-type="supplementary-material"} and [S3C](#SD1){ref-type="supplementary-material"}--[S3E](#SD1){ref-type="supplementary-material"}). Detection of tdTomato^+^ lineage-restricted hematopoietic progenitors suggests that these cells were either directly transduced by AAV-Cre or that they arose from a more upstream precursor cell within the 14 days after AAV injection.

To determine whether the *in vivo* transduced tdTomato^+^ HSCs detected by immunophenotyping retained stem cell engraftment, self-renewal, and differentiation potential, we applied rigorous primary and secondary transplantation assays to evaluate the long-term reconstituting function of HSCs transduced by AAV-Cre. We isolated Lin^low^ tdTomato^+^ bone marrow cells by FACS from AAV-Cre-injected Ai9 mice expressing the CD45.2 allotype and transplanted these cells into lethally irradiated congenic CD45.1^+^ recipients ([Figure 3A](#F3){ref-type="fig"}). Monthly assessments of peripheral blood chimerism revealed high levels of donor (CD45.2^+^) cell engraftment among all primary transplant recipients ([Figure 3D](#F3){ref-type="fig"}). In addition, all recipients exhibited enduring contributions of tdTomato^+^ CD45.2^+^ donor-derived peripheral blood cells in multiple hematopoietic lineages at 16 weeks post-transplant ([Figures 3E](#F3){ref-type="fig"}--[3I](#F3){ref-type="fig"}). Analysis of tdTomato expression in the bone marrow further revealed the presence of donor-derived CD45.2^+^ tdTomato^+^ HSCs in 45 of 46 recipient mice analyzed ([Figure 3J](#F3){ref-type="fig"}). The detection of tdTomato^−^ CD45.2^+^ donor-derived peripheral blood cells and HSCs in the transplanted recipients likely reflects our decision to perform single, rather than double, sorts to maximize cell yield over cell purity ([Figures 3F](#F3){ref-type="fig"}--[3J](#F3){ref-type="fig"}).

We next performed secondary transplantation of bone marrow cells from a subset of previously engrafted primary recipient mice ([Figure 3A](#F3){ref-type="fig"}). Analysis of donor chimerism levels within secondary recipients revealed a range of approximately 20%--80% among peripheral blood cells ([Figure 4A](#F4){ref-type="fig"}). Of these secondary recipients, a majority showed multilineage engraftment by tdTomato^+^ donor cells at 16 weeks post-transplant ([Figures 4B](#F4){ref-type="fig"}--[4F](#F4){ref-type="fig"}). Moreover, tdTomato^+^ donor-derived HSCs were detected in the bone marrow of secondary recipients 4--5 months post-transplant ([Figure 4G](#F4){ref-type="fig"}), providing functional evidence that AAV-Cre transduced long-term reconstituting HSCs within the initial injected animals, rather than long-lived oligolineage progenitors ([@R7]; [@R35]; [@R40]). We also evaluated transduction of HSCs following local injection of AAV serotypes 1, 2, 5, 6, 8, 9, 10, and Anc80, with immunophenotypically ([Figures S4A](#SD1){ref-type="supplementary-material"} and [S4B](#SD1){ref-type="supplementary-material"}) and functionally ([Figures S4C](#SD1){ref-type="supplementary-material"}--[S4F](#SD1){ref-type="supplementary-material"}) defined tdTomato^+^ HSCs and tdTomato^+^ hematopoietic progenitors ([Table S2](#SD1){ref-type="supplementary-material"}) detected in the bone marrow in multiple AAV-injected animals. Altogether, these data provide strong evidence that local or systemic injection of any of several AAV serotypes encoding a sequence-specific DNA-modifying enzyme can allow for transduction of multiple subsets of endogenous bone marrow stem and progenitor cells, including the most primitive, long-term reconstituting HSCs. This strategy enables irreversible genomic modification, sustained through multiple rounds of hematopoietic regeneration as assayed in transplantation assays, of long-term reconstituting HSCs residing within their native niche.

Lastly, to extend our analysis beyond skeletal muscle and hematopoietic tissues, we collected skin tissue from a subset of animals injected with high-dose AAV8-Cre and evaluated whether systemic delivery of AAV might also transduce discrete precursor cell populations within this well-defined anatomical compartment. We observed tdTomato fluorescence within hematopoietic cells localized in the skin (CD45^+^, ranging from 7% to 22%) ([Figures S5A](#SD1){ref-type="supplementary-material"}, [S5B](#SD1){ref-type="supplementary-material"}, and [S5H](#SD1){ref-type="supplementary-material"}), as expected from our bone marrow analyses, and in dermal fibroblasts ([Figure S5C](#SD1){ref-type="supplementary-material"}) marked by CD140a expression (also known as Pdgfra) ([@R12]). Using flow cytometry, we evaluated tdTomato expression within four populations of CD45^−^CD140a^+^ dermal fibroblasts, distinguishable by combinatorial expression of CD24 and Sca-1 ([Figure S5A](#SD1){ref-type="supplementary-material"}) ([@R48]). tdTomato fluorescence was detected in each of these dermal subsets, including adipocyte precursors (CD24^+^Sca-1^+^, ranging from 8% to 26%) ([Figures S5E](#SD1){ref-type="supplementary-material"} and [S5H](#SD1){ref-type="supplementary-material"}), dermal papilla cells (CD24^−^Sca-1^−^, ranging from 13% to 20%) ([Figures S5F](#SD1){ref-type="supplementary-material"} and [S5H](#SD1){ref-type="supplementary-material"}), and two populations of dermal fibroblasts (CD24^+^Sca-1^−^, ranging from 2% to 4%, and CD24^−^Sca-1^+^, ranging from 16% to 27%) ([Figures S5D](#SD1){ref-type="supplementary-material"}, [S5G](#SD1){ref-type="supplementary-material"}, and [S5H](#SD1){ref-type="supplementary-material"}). Thus, systemically administered AAVs target multiple immunophenotypically distinct cell populations in mammalian skin, including precursors of dermal adipose and connective tissue that support epidermal homeostasis and regeneration (reviewed in [@R13]). In concert with the analyses of skeletal muscle and bone marrow cell populations presented earlier, these data demonstrate the utility of systemic AAV administration to accomplish direct genome modification in multiple adult cell lineages and within anatomically distinct tissue compartments.

DISCUSSION {#S3}
==========

In this study, we document efficient delivery of DNA-modifying enzymes by AAVs to enable permanent genome modifications within tissue stem cell populations *in vivo*. This highly programmable approach demonstrates effectiveness in three lineages of stem and progenitor cells (myogenic, mesenchymal, and hematopoietic), and in three distinct anatomical niches (skeletal muscle, bone marrow, and skin) and is highly likely to be generalizable to other DNA-modifying enzymes, including CRISPR/Cas-based systems, as well as additional regenerative cell types in other organ systems and species. A distinct advantage of our approach is that it allows for manipulation of stem cell genomes *in situ* without requiring cell isolation, culture, or subsequent transplantation, thereby preserving native regulatory interactions and extant stem cell properties. This system also mitigates challenges and toxicities associated with *ex vivo* stem cell modification and subsequent transplantation, such as the failure of *in vitro* conditions to maintain robust stem cell function, the necessary use of ablative conditioning, and the unavoidable risk of graft failure ([@R30]). We anticipate that the opportunity to directly transduce endogenous tissue stem cells with DNA-modifying enzymes will be of direct and specific relevance for ongoing academic and commercial efforts aimed at therapeutic gene editing in stem cells, all of which have, to this point, considered it necessary to purify stem cells for *ex vivo* modification and re-infusion ([@R30]).

A key finding of our work is that AAVs can efficiently transduce multiple adult tissue stem and progenitor cell types *in vivo*. These results contrast to some degree with previous reports concluding that AAVs do not effectively transduce skeletal muscle satellite cells in adult animals following local or systemic administration ([@R2]; [@R9]; [@R10]). In one of these prior studies ([@R2]), systemic administration of AAV6 encoding CMV-driven EGFP into 4-week-old mice did not result in detectable Pax7^+^/EGFP^+^ satellite cells 4 weeks after injection. Meanwhile, intramuscular administration of AAV6 or AAV9 encoding CMV-EGFP into 8-week-old mice resulted in no detectable Pax7^+^/EGFP^+^ satellite cells 2 weeks post-injection, while similar administration of AAV8-CMV-EGFP resulted in a minority (\<5%) of the satellite cell compartment expressing EGFP ([@R2]). One potential explanation for these discrepancies could be that our study used a more sensitive Cre/lox-driven system to robustly drive tdTomato fluorescence from the mouse genome in the AAV-transduced cells and their progeny, as opposed to monitoring expression of the introduced EGFP protein encoded by the AAV genome, which may exhibit transient expression. Ultimately, our results demonstrate that AAVs are capable of transducing satellite cells at efficiencies required for therapeutic gene editing. Our approach, in which cells are permanently modified following AAV transduction, also allowed us to detect delivery of AAV cargo to non-myogenic stem and progenitor cells, including bone marrow localized HSCs. While detection in recent years of naturally occurring clade F AAV variants in healthy human CD34^+^ hematopoietic cells (termed AAVHSC) ([@R39]) suggests the existence of AAVs that can transduce such cells, our report demonstrates the efficient *in vivo* transduction of these cells by recombinant AAV vectors and confirms the preservation of HSC function post-transduction using immunophenotyping and transplantation assays. Still, it will be important in future studies to investigate whether AAV transduction influences global gene expression levels within stem cell populations and whether AAVs preferentially transduce certain subsets of tissue stem cells over others.

In addition to targeting muscle satellite cells and HSCs, our finding that AAVs transduce mesenchymal progenitor cells *in vivo* has important potential applications for this cell population. Mesenchymal progenitors are well-established regulators of myogenesis ([@R18]), and they represent a major source of fibrosis and adipose deposition in aging and muscle disease ([@R18]; [@R24]; [@R43], [@R44]). Thus, these cells are potential targets for anti-fibrotic interventions or for manipulations that will promote their promyogenic activities. In addition, because little is known about the mechanisms that govern the actions of these cells, including regulators of their proliferation, differentiation, or role in trophic support for muscle, we anticipate that targeting this population of cells could be useful for revealing such mechanisms and for advancing our understanding of muscle maintenance and regeneration. This in turn could lead to therapeutic interventions that mitigate the detrimental impacts of these cells and promote their pro-myogenic activity. Given the large number of studies that have used Cre models to manipulate gene expression in these cells for such purposes ([@R15]; [@R20]; [@R21]; [@R34]), we anticipate that our system provides an alternative and in some cases more facile system for gene manipulation, which will be of interest to researchers seeking to uncover the biology of this unique class of tissue progenitors.

Our current and prior efforts to target tissue stem and progenitor cells using AAV-mediated delivery of Cre or CRISPR complexes ([@R41]) establish a broadly accessible platform for *in vivo* delivery of genome-modifying enzymes. One key difference between using AAVs to deliver Cre recombinase and using CRISPR is whether a single- or dual-vector system is necessary to deliver the desired components. In this study, we delivered Cre-recombinase via a single AAV, such that any cell that received the AAV cargo would have sufficient genetic material to execute Cre-mediated genome modification. However, extending this approach to more complex CRISPR/Cas-based systems involving Cas9 and multiple guide RNAs may require co-transduction with multiple AAV vectors due to the limited \~ 4.7-kb packaging capacity of AAVs. In our previously published study ([@R41]), we co-administered two AAVs to perform *in vivo* CRISPR editing: one AAV encoding CMV-driven saCas9 and a second AAV encoding two U6-driven guide RNAs targeting the locus of interest ([@R41]). While we did observe CRISPR-mediated targeting using this dual-vector system, future efforts to harness minimal stem cell-specific promoters could reduce this approach to a single-vector system, which may improve editing efficiency.

An important consideration regarding the potential applicability of AAV-mediated transduction of tissue stem cells to humans is the impact of an induced immune response to repeated AAV dosing. This issue has been extensively reviewed elsewhere, and it has not precluded clinical testing of AAV-based therapeutics for various diseases in human populations ([@R11]; [@R29]). An additional consideration for translating these findings to humans is the dose of AAV necessary to achieve sufficient transduction of tissue stem and progenitor cells, because a report suggested that high-dose systemic administration of AAV can induce liver toxicity ([@R17]). The AAV doses used in our studies reported here are comparable with those used in many therapeutically oriented preclinical studies in mice ([@R4]; [@R9]; [@R23]; [@R31]; [@R41]; [@R47]) and canines ([@R1]), as well as those used in successful human trials for spinal muscular atrophy gene therapy ([@R28]). While we did not observe overt signs of liver toxicity in the mice in our study ([Figure S6](#SD1){ref-type="supplementary-material"}), we acknowledge that this issue remains an important consideration for future development of AAV-based therapeutics.

The *in vivo* AAV system described here also overcomes critical technological and practical limitations associated with current experimental systems for interrogating stem cell function. In particular, commonly employed transgenic and gene knockout-based models frequently require complex breeding schemes to introduce multiple alleles, necessitating significant investment of both time and resources. Such approaches become even more challenging when assessing gene-targeting effects in aged animals, in non-standard genetic backgrounds, or in a combinatorial fashion. In contrast, AAV-mediated delivery of programmable DNA-modifying enzymes can be applied across a range of animal ages and strains and to various individual and multiplexed genetic loci. In addition, the AAV-Cre strategy used here provides an alternative and complementary approach to tamoxifen-inducible Cre- (CreER) dependent gene activation or inactivation strategies that additionally enables researchers to bypass the potentially confounding effects of hormone administration ([@R32]). This technology is therefore likely to have important applications in accelerating the pace at which gene functions and interactions can be interrogated *in vivo* and in tissue progenitors. Our results also indicate that multiple AAV serotypes exhibit tropism for tissue stem and progenitor cells, establishing a foundation for the development of more specific and selective systems, including identification of AAV capsid variants that transduce particular stem cell populations and of naturally occurring or synthetic gene regulatory elements that restrict expression of AAV-encoded genes to only these cell types. Ultimately, this system may be adapted to enable rapid and direct *in vivo* screening of candidate and unknown gene targets suspected to specifically influence stem cell phenotypes.

STAR★METHODS {#S4}
============

CONTACT FOR REAGENT AND RESOURCE SHARING {#S5}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Amy Wagers (<amy_wagers@harvard.edu>).

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S6}
--------------------------------------

### Mice {#S7}

Mice were housed at the animal facility at the Harvard University/Faculty of Arts and Sciences Biological Research Infrastructure, which is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AALAC). All procedures were performed under protocols approved by the Institutional Animal Care and Use Committee (IACUC). Mice were housed in standard ventilated racks at a maximum density of 5 mice per cage. Room temperature was maintained at 22°C ± 1°C with 30%--70% humidity. Mice were kept on a 12-hour light/dark cycle and provided food and water *ad libitum*. Breeder mice were kept on irradiated PicoLab Mouse Diet 20 5058 (LabDiet, St. Louis, MO), and non-breeder mice were kept on irradiated LabDiet Prolab Isopro RMH 3000 5P75 (LabDiet, St. Louis, MO). Cages were filled with 1/4 inch Anderson's Bed o Cob bedding (The Andersons, Inc., Maumee, OH) and each contained one nestlet (2 × 2" compressed cotton square, Ancare, Bellmore, NY) and one red mouse hut (certified poly-carbonate; 3 3/4" wide x 1 7/8" tall x 3" long, BioServ, Flemington, NJ). Cage changes were performed at least every 14 days, and more frequently if necessary. Animal health surveillance was performed quarterly by PCR testing of index animals and through swabs from rack plenums.

C57BL/10ScSn-Dmd^*mdx*^/J (*mdx*; C57BL/10ScSnJ background), B6;129S6-*Gt(ROSA)26Sortm9(CAG-tdTomato)Hze*/J (Ai9; B6/129S6 background), B6.SJL-*Ptprc*^*a*^ *Pepc*^*b*^/BoyJ (CD45.1; C57BL/6J background), B6.Cg-Tg(Pax7-ZsGreen)1Kyba/J (*Pax7-ZsGreen*; C57BL/6J background) and C57BL/6J mouse strains were used for this study. To generate *mdx*; Ai9 homozygous mice, *mdx* mice were bred to Ai9 homozygous mice. *mdx*; Ai9 mice were bred with *Pax7-Zsgreen* mice to generate *mdx*;Ai9*;Pax7-Zsgreen* animals. The *Pax7-zsGreen* allele has been extensively validated in multiple studies to mark skeletal muscle satellite cells by flow cytometry ([@R3]; [@R6]; [@R27]). Animals were randomly assigned to experimental and control groups. All mice used for experiments were immunocompetent.

For intrafemoral injection experiments, 6--9-month-old male and female Ai9 homozygous animals were injected with AAV-Cre or vehicle. 6 weeks post injection, mice were euthanized and hematopoietic cells were isolated for flow cytometry analysis and FACS. For systemic injection experiments, 6-week-old male *mdx*; Ai9 homozygous mice were injected with AAV-Cre or vehicle via tail vein or retroorbital injection. 2 weeks post injection, mice were harvested and liver, skeletal muscle and hematopoietic cells were collected for analysis. Histopathological assessment of hematoxylin & eosin stained sections of liver tissue from a subset of AAV-Cre and control-injected animals, performed in a blinded fashion by a skilled mouse pathologist (R. Bronson), did not reveal signs of tissue pathology ([Figure S6B](#SD1){ref-type="supplementary-material"}).

For hematopoietic cell transplantation experiments, bone marrow cells from homozygous CD45.1 mice were collected and depleted for Sca-1 to use for helper marrow. Homozygous CD45.1 mice were used as recipients for primary and secondary hematopoietic stem and progenitor cell (HSPC) transplants. Following HSPC transplantation, recipient animals were kept on antibiotic water containing 0.67mg/mL Sulfadiazine Trimethoprim for 4 weeks post-transplant.

METHOD DETAILS {#S8}
--------------

### AAV selection and production {#S9}

Multiple AAV serotypes were used, with a particular emphasis on serotypes with broad biodistribution ([@R49]). For the intrafemoral injection experiments, we evaluated a panel of 7 AAV serotypes (1, 2, 5, 6, 8, 9 and 10) and identified those that targeted HSCs with the greatest efficiency. A smaller panel of 3 AAV serotypes (1, 8, 9) was used for the intramuscular injection experiments. We did not move forward with AAV1 for the systemic injection experiments because it is known to induce a greater inflammatory response than the other AAV serotypes ([@R25]), which may limit its usefulness in preclinical testing or in disease modeling applications. The selection of AAV serotypes used for the systemic injection experiments was based on our previous work showing that AAV9 effectively transduces muscle satellite cells *in vivo* ([@R41]). For our preliminary analyses ([Table S1](#SD1){ref-type="supplementary-material"}), we administered AAV9 via tail vein injection along with two additional serotypes: AAV6 and AAV8, both of which have been shown to target skeletal muscle following *in vivo* delivery ([@R5]; [@R46]). Building off of these results, we next performed systemic tail vein administration of AAV8 and AAV9, and also included Anc80L65, an ancestral AAV with robust tropism for skeletal muscle and other organs ([@R50]), to express Cre recombinase downstream of CMV promoter and a chimeric intron. For systemic retro-orbital AAV administration, we focused particularly on Anc80 and AAV8, both of which exhibited higher targeting efficiency for blood and muscle stem cells in the tail vein injection experiments. Furthermore, we included two doses of AAV8 to assess if injecting a higher concentration of AAV resulted in a greater transduction efficiency.

For systemic injection experiments using AAV8, AAV9 and Anc80L65, AAV production was performed by the Gene Transfer Vector Core (GTVC) at the Grousbeck Gene Therapy Center at the Schepens Eye Research Institute and Massachusetts Eye and Ear as described previously ([@R22]; [@R50]). For intrafemoral injection experiments using AAV serotypes 1, 2, 5, 6, 8, 9 and 10, AAVs were produced at the University of Pennsylvania Penn Vector Core. For the systemic injection experiment using AAV6, AAV8, and AAV9, AAV production was done by the UMASS medical school vector core.

### Muscle stem cell isolation and *in vitro* differentiation {#S10}

Muscle stem cell isolation from *mdx*;Ai9 mice systemically injected with AAV-Cre was performed as previously described ([@R8]; [@R38]). Briefly, tibialis anterior (TA), gastrocnemius, triceps, quadriceps and abdominal muscles were digested with collagenase and dispase and myofiber-associated cells were isolated by centrifugation. The cells were stained with an antibody mix (APC-Cy7 anti-CD45 (1:200), APC-Cy7 anti-CD11b (1:200), APC-Cy7 anti-TER119 (1:200), APC anti-Sca-1 (1:200), FITC anti-CD29 (β1-integrin) (1:100), Biotin anti-CD184 (CXCR4) (1:100)) for 30 min on ice, followed by a secondary staining with Streptavidin-PE-Cy7 (1:100) for 15 minutes on ice. Propidium iodide (PI) and calcein blue were used to discriminate dead and live cells, respectively. CD45^−^ CD11b (Mac-1)^−^ Ter119^−^ Sca-1^−^ β1-integrin^+^ CXCR4^+^ cells were isolated by FACS as muscle satellite cells;Sca-1^+^, CD45^−^ CD11b^−^ Ter119^−^ cells were isolated as mesenchymal progenitors; Lineage (CD45, CD11b, Ter119)^+^ cells were gated as Lin^+^ blood cells for analysis. For *in vitro* expansion of satellite cells isolated from AAV-transduced muscles, satellite cells were seeded on collagen/laminin-coated plates in F10 containing 20% donor horse serum, 1% penicillin-streptomycin, and 1% glutamax. 5 ng/ml bFGF was added to the medium daily. Media was refreshed every other day. After 5 days, satellite cells were harvested, cell numbers were counted and cells were re-plated in multiple wells of a 96 well plate for differentiation. The next day, media was changed to DMEM containing 2% donor horse serum and 1% penicillin-streptomycin. Myotubes were fixed with 4% paraformalde-hyde after 60 or 72 hours in differentiation media.

Muscle stem cell isolation from AAV-Cre injected TA muscles of *mdx;Pax7-ZsGreen*^+/−^;Ai9 mice was performed as previously described ([@R41]). Briefly, individual TA muscles were separately minced using scissors followed by two digestion steps in collagenase and dispase. Muscles were triturated in between and after the digestion steps. The homogenate was centrifuged, re-suspended, and filtered before another round of centrifugation and resuspension. Cells were stained with an antibody mix of APC anti-Sca-1 (1:200), APC-Cy7 anti-CD45 (1:200), APC-Cy7 anti-CD11b (Mac-1) (1:200), and APC-Cy7 anti-Ter119 (1:200). Propidium iodide (PI) and calcein blue were used to discriminate dead and live cells, respectively. CD45^−^ CD11b (Mac-1)^−^Ter119^−^ Sca-1^−^ *Pax7-ZsGreen*^+^ cells were isolated as muscle satellite cells. This transgenic line has been used previously in multiple studies for the identification and isolation of muscle satellite cells, with extensive validation studies performed by multiple groups ([@R3]; [@R6]; [@R27]), including a study from our lab which specifically addressed the issue of satellite cell identification by flow cytometry ([@R27]).

### Muscle Sca-1^+^ progenitor isolation and adipogenic differentiation {#S11}

Sca-1^+^ progenitor (Sca-1^+^, CD45^−^ CD11b (Mac-1)^−^ Ter119^−^) isolation from *mdx*;Ai9 mice systemically injected with AAV-Cre was performed as previously described ([@R16]; [@R36]; [@R42]). Briefly, freshly sorted Sca-1^+^ cells were plated in collagen/laminin-coated 96 well plates and expanded for 8 days in growth medium (F10 containing 20% donor horse serum, 1% penicillin-streptomycin, and 1% glutamax) and provided with 5 ng of bFGF daily with fresh media changes every other day. After 8 days in growth medium, cells were switched to Adipogenic Induction Media (DMEM containing 10% FBS, 1% penicillin/streptomycin, 1 mM Dexamethasone, 100 nM Insulin, 1 mM Rosiglitazone and 0.5 mM 3-isobutyl-1-methylxanthine) for 2 days and then switched to Adipogenic Differentiation Media (DMEM containing 10% FBS, 1% penicillin/streptomycin and 100 nM Insulin) for an additional 8 days. Media was changed every other day, and cells were stained with BODIPY™ 493/503 as per manufacturer's instructions.

### Muscle satellite cell transplantation {#S12}

One day before transplantation, 25 μL of 10 μM Cardiotoxin gamma from Naja pallida was injected to the tibialis anterior (TA) muscles of anesthetized 7--8 week-old male *mdx* recipient mice. Up to 50,000 single-sorted tdTomato^+^ satellite cells or vehicle (staining media) alone was injected into the pre-injured tibialis anterior (TA) muscles. The injected TA muscles were harvested 3 weeks post-transplantation for cryosectioning and fluorescence detection.

### Immunofluorescence {#S13}

For myosin heavy chain (MHC) staining of *in vitro* differentiated myotubes, myotubes were permeabilized using 0.5% Triton X-100 for 15 minutes at room temperature, washed 2 × 5 minutes with DPBS, and blocked with 5% Normal Goat Serum, 2% BSA, 2% protein concentrate (from M.O.M.™ Basic Kit), and 0.1% Tween-20 for 1 hour at room temperature. Cells were washed 2 × 5 minutes with DPBS, incubated with anti-skeletal myosin type II (fast-twitch) (1:200) and anti-skeletal myosin type I (slow-twitch) (1:100) at 4°C overnight, washed 3 × 5 minutes with DPBS, and incubated with goat anti-mouse IgG Alexa 488 conjugate secondary antibody (1:250). After washing for 3 × 5 minutes with DPBS, cells were stained with 10 mg/ml Hoechst.

For staining of skeletal muscle tissue, tibialis anterior (TA) muscles were dissected and immediately fixed in 1% PFA for one hour at room temperature, washed with DPBS, and cryopreserved in 30% sucrose at 4°C overnight. Tissues were then embedded in O.C.T. compound, cryopreserved in super-cooled isopentane, and sectioned using a Leica CM1860 cryostat (Leica Biosystems). Sections were post-fixed in 2% PFA for 5 minutes, incubated in 0.1 M glycine buffer for 5 minutes, and permeabilized in 0.3% Triton X-100/DPBS for 20 minutes. Sections were blocked with 10% M.O.M. IgG blocking reagent, and further blocked with 1% M.O.M. IgG blocking reagent, 3% BSA, 8% M.O.M protein concentrate, and 5% Normal Goat Serum. Primary antibody staining was performed using anti-Pax7 (15 μg/mL) and Rabbit anti-laminin (1:200) at 4°C overnight. The following day, sections were washed and stained with goat anti-mouse IgG1 Alexa Fluor 488 (1:250) and goat anti-rabbit IgG H^+^L Alexa Fluor 647 (1:250). Slides were mounted with VectashieldHardSet Antifade Mounting Medium containing DAPI, and images were captured using a Zeiss LSM 880 inverted confocal microscope. For quantification of Pax7^+^ tdTomato^+^ sublaminar cells by immunofluorescence analysis, 60--80 Pax7^+^ sublaminar cells were quantified per animal among 10 0.181mm^2^ fields.

For staining of skin tissue, dorsal skin samples were fixed for 15 minutes using 4% PFA at room temperature, washed extensively with PBS, immersed in 30% sucrose overnight at 4°C and embedded in O.C.T. 30 μM sections were blocked for 1--2 hours (5% Donkey serum, 1% BSA, 2% Cold water fish gelatin in 0.3% Triton in PBS), incubated with anti-CD140a (1:200) and anti-RFP (1:1000) antibodies overnight at 4°C and incubated for 2--4 hours at room temperature with Donkey anti-goat IgG Alexa 488 (1:400) or Donkey anti-rabbit Cy3 (1:400) secondary antibodies. DAPI was used for counterstaining.

### RNA isolation, cDNA synthesis and Real-time PCR {#S14}

Satellite cells were sorted directly into Trizol LS and stored at −80°C. Total RNA was isolated according to manufacturer's instructions. cDNA was synthesized using the SuperScript IV VILO Master Mix with ezDNase Enzyme kit. Quantitative PCR was performed on a QuantStudio 6 Flex Real-Time PCR system. The following TaqMan assays were used to evaluate relative gene expression: *Pax7* (Mm01354484_m1), *Myf5* (Mm00435125_m1), *Myod1* (Mm00440387_m1), *Myog* (Mm00446194_m1) and *Gapdh* (Mm99999915_g1).

### HSPC Isolation and Flow Cytometry Analysis/FACS {#S15}

Bone marrow cells were flushed from all 4 long bones (2 femurs and 2 tibias) with a 21-gauge needle into staining media (HBSS containing 2%FBS), resuspended, and filtered through a 40 μm cell strainer. Cells were pelleted and subjected to ACK lysis for 5 minutes on ice (except when analyzing erythroid precursor cells), re-filtered through a 40 μm strainer, and washed with staining media.

To identify HSCs from AAV-injected mice, cells were stained with the following antibodies for 45 minutes on ice: CD3-ef450 or CD3-biotin (1:100), B220-ef450 or B220-biotin (1:200), Ter119-ef450 or Ter119-biotin (1:100), Gr-1-ef450 or Gr-1-biotin (1:400), CD11b-APC-Cy7 (1:200), c-Kit-APC (1:200), Sca-1-PE-Cy7 (1:200), CD48-FITC (1:200), and CD150-BV510 (1:50). When biotinylated antibodies were used, cells were washed and incubated with Streptavidin-ef450 (1:200) for 30 minutes on ice.

To identify HSCs from transplanted mice, cells were stained with the following antibodies for 45 minutes on ice: Lineage Cocktail-Pacific Blue (1:20), c-Kit-APC (1:200), Sca-1-PE-Cy7 (1:200), CD48-FITC (1:200), CD150-BV510 (1:50), and CD45.2-AF700 (1:100).

To identify myeloid progenitors from AAV-injected mice, cells were stained with the following antibodies for 60 minutes on ice: CD3-ef450 or CD3-biotin (1:100), B220-ef450 or B220-biotin (1:200), Ter119-ef450 or Ter119-biotin (1:100), Gr-1-ef450 or Gr-1-biotin (1:400), CD11b-APC-Cy7 (1:200), c-Kit-APC (1:200), Sca-1-PE-Cy7 (1:200), CD34-FITC (1:25) and CD16/CD32-AF700 (1:100). For biotinylated antibodies, cells were washed and incubated with Streptavidin-ef450 (1:200) for 30 minutes on ice.

To identify erythroid precursor cells from AAV-injected mice, cells were stained with the following antibodies for 30 minutes on ice: CD71-FITC (1:200) and Ter119-APC (1:200).

For all HSPC staining panels, cells were washed after antibody/streptavidin incubation and resuspended in staining media, and Sytox Blue (1:1,000) was added immediately prior to FACS to mark dead cells. Cells were analyzed on a BD LSR II flow cytometer and sorting was performed on a BD FACS Aria II. Data analysis was performed using BD FACS Diva and FlowJo software.

### HSPC Transplantation {#S16}

For each animal, Lin^low^ tdTomato^+^ live bone marrow cells were singly sorted from bone marrow into staining media containing 10% FBS. As CD11b (Mac-1) expression has been reported to increase on HSCs in certain contexts of inflammation or stress ([@R33]), we did not sort tdTomato^+^ bone marrow cells for transplantation on the basis of CD11b expression, in case this marker might be altered in its expression following AAV administration. Cells from each donor animal were combined with 6×10^5^ Sca-1-depleted radioprotective CD45.1 helper bone marrow cells and injected intravenously into two lethally irradiated (950 rads, split dose) anesthetized CD45.1 recipient animals (3×10^5^ helper marrow cells per recipient). Cells were injected with a 28-gauge insulin syringe into the retroorbital sinus.

Sca-1 depletion was performed by staining ACK-lysed CD45.1 bone marrow cells with Sca-1-APC (1:200) for 10 minutes on ice, washing and incubating with anti-APC microbeads for 20 minutes on ice. Cells were washed and depleted using the AutoMACS Separator (Depletes program). Depletion efficiency was confirmed by flow cytometry analysis. 7-AAD (1:20) was used as a viability dye and was added to cells immediately prior to analysis.

### Peripheral blood collection and flow cytometry analysis {#S17}

Donor chimerism and tdTomato analysis was performed from peripheral blood samples of primary and secondary transplant recipients at 4, 8, 12 and 16 weeks post-transplant. Peripheral blood was collected via the tail vein into a 1.5mL tube containing 100 μL of PBS/10mM EDTA and stored on ice. 1mL of 2%Dextran/PBS was added to the samples, mixed and incubated at 37°C for 30 minutes to sediment red blood cells. The remaining cells were washed and subjected to ACK lysis for 5 minutes on ice. Cells were washed, filtered through a 40 μm cell strainer, and resuspended in HBSS/2% FBS/10mM EDTA containing anti-CD16/CD32 (1:50) for 5 minutes on ice. Cells were stained with the following antibodies for 30 minutes on ice: CD3-PE-Cy7 (1:65), B220-FITC (1:100), CD11b-APC-Cy7 (1:200), Gr-1-Biotin (1:400), CD45.1-Pacific Blue (1:100) and CD45.2-APC (1:100). Cells were washed and stained with Streptavidin-Pacific Orange (1:500) for 30 minutes on ice. Cells were washed, resuspended in HBSS/2% FBS/10mM EDTA, and 7-AAD (1:20) was added immediately prior to analysis. Cells were analyzed on a BD LSR II flow cytometer, and data analysis was performed using BD FACS Diva and FlowJo software.

### Liver histology {#S18}

Liver tissue was harvested and fixed in 4% paraformaldehyde for approximately 24 hours, then transferred to 70% ethanol. Samples were submitted to the Rodent Histopathology Core at the Dana-Farber/Harvard Cancer Center, embedded in paraffin, sectioned and stained with hematoxylin and eosin. Slides were analyzed and scored for histopathology by a Rodent Histopathologist in a blinded manner.

### Skin cell isolation and flow cytometry analysis {#S19}

Mouse back skin was dissected. Dissected skin (dermis facing down) was incubated in 0.25% Collagenase in HBSS for 40--60 minutes at 37°C. The dermis was then scraped using a surgical scalpel. Collected cells were centrifuged for 8 minutes at 350xg at 4°C.Single cell suspensions were obtained by incubation with trypsin-EDTA at 37°C for 10 minutes and filtering through 70 μM and 40 μM filters. Single cell suspensions were then centrifuged for 8 minutes at 350xg at 4°C, re-suspended in 5% FBS in PBS and stained for 30 minutes. The following antibodies were used: CD45-ef450 (1:250), CD140a-biotin (1:250), Streptavidin-APC (1:500), CD24-FITC (1:200), and Sca-1-PerCP-Cy5.5 (1:1000). DAPI was used to exclude dead cells. Blood-lineage cells were gated as CD45^+^. Dermal fibroblasts were gated as CD45^−^ CD140a^+^, then further divided based on CD24 and Sca-1 expression. Cells were analyzed on a BD FACS Aria II, and data analysis was performed using BD FACS Diva and FlowJo software.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S20}
---------------------------------------

GraphPad Prism software was used to perform statistical analyses. For the real-time PCR analysis, paired t test was used to calculate statistical significance between the two groups. Repeated-measures ANOVA was used for longitudinal analyses of donor chimerism. Results with a p value \< 0.05 were considered statistically significant. Information on replicates is reported in the figure legends.
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![Systemic AAV-Cre Administration Transduces Muscle Satellite Cells\
(A) Experimental design. AAVs encoding Cre recombinase were injected into *mdx*;Ai9 mice, which carry a *Rosa26*-LSL-tdTomato reporter. i.v., intravenous; LSL, LoxP-STOP-LoxP.\
(B) Representative flow cytometric analysis of skeletal muscle satellite cells isolated from *mdx*;Ai9 mice injected intravenously with AAV-Cre packaged in various serotypes at a low dose (\~5.5 × 10^11^ to 8 × 10^11^ vg) or a high dose (\~2.2 × 10^12^ vg). MuSCs, muscle satellite cells.\
(C) Quantification of the frequency of AAV-transduced and Cre-recombined tdTomato^+^ muscle satellite cells.\
Data points from individual mice are overlaid with mean ± SD. n = 4 mice injected with each AAV serotype per group, n = 3 vehicle-injected mice per group. vg, viral genomes; Anc80, Anc80L65.\
See also [Figures S1](#SD1){ref-type="supplementary-material"}, [S2](#SD1){ref-type="supplementary-material"}, [S5](#SD1){ref-type="supplementary-material"}, and [S6](#SD1){ref-type="supplementary-material"} and [Table S1](#SD1){ref-type="supplementary-material"}.](nihms-1527710-f0002){#F1}

![AAV-Transduced Muscle Satellite Cells Retain Differentiation and Engraftment Potential\
(A) Representative immunofluorescence images of myosin heavy chain (MHC)-stained myotubes differentiated from muscle satellite cells isolated from mice injected with different AAV serotypes at low or high doses. Green, MHC; red, tdTomato; blue, Hoechst. Scale bar, 100 μm. Anc80, Anc80L65.\
(B) Representative immunofluorescence images analyzing satellite cell engraftment in tibialis anterior (TA) muscles from *mdx* mice that either were not transplanted (top row, control) or were transplanted with 50,000 FACS-purified tdTomato^+^ muscle satellite cells from high-dose AAV8-Cre-injected Ai9 mice (bottom row). TA muscles from 2 transplanted legs and 2 non-transplanted contralateral legs were analyzed 3 weeks post-transplantation. White arrowheads denote Pax7^+^ tdTomat^−^ muscle satellite cells. White arrows denote Pax7^+^ tdTomato^+^ muscle satellite cells. tdTomato^+^ myofibers are also apparent. Blue, DAPI; white, laminin; green, Pax7; red, tdTomato. Scale bar, 20 μm.\
(C) Representative images analyzing muscle fiber engraftment in TA muscles from *mdx* mice 3 weeks after injection of vehicle only (top row, control) or of muscle satellite cells harvested from *mdx*;Ai9 mice injected previously with high-dose AAV8-Cre (bottom row). Red, tdTomato; green, wheat germ agglutinin (WGA); blue, DAPI. Scale bar, 100 μm.\
See also [Figures S1](#SD1){ref-type="supplementary-material"}, [S2](#SD1){ref-type="supplementary-material"}, [S5](#SD1){ref-type="supplementary-material"}, and [S6](#SD1){ref-type="supplementary-material"} and [Table S1](#SD1){ref-type="supplementary-material"}.](nihms-1527710-f0003){#F2}

![Systemic Injection of AAV-Cre Transduces Functional Hematopoietic Stem Cells\
(A) Experimental design. AAVs encoding Cre recombinase were injected into *mdx*;Ai9 mice carrying the *Rosa26*-LSL-tdTomato reporter. i.v., intravenous; LSL, LoxP-STOP-LoxP; HSPCs, hematopoietic stem and progenitor cells.\
(B) HSC gating strategy (Lin^−^Sca-1^+^c-Kit^+^CD48^−^CD150^+^) from bone marrow (BM) and representative flow cytometric analysis of tdTomato expression within HSCs. LSK: Lin^−^Sca-1^+^c-Kit^+^.\
(C) Frequency of HSCs expressing tdTomato. Data points from individual mice are overlaid with mean ± SD. n = 4 mice injected with each AAV serotype per group, n = 3 vehicle-injected mice per group.\
(D) Percentage of donor chimerism among live peripheral blood cells of primary recipients at monthly intervals post-transplantation. Data points represent mean ± SD. n = 8 primary recipients per group.\
(E) Frequency of primary recipients with tdTomato^+^ multilineage engraftment within the indicated peripheral blood lineages at 16 weeks post-transplant. For each lineage, tdTomato^+^ engraftment was scored based on satisfaction of two criteria: \>1% CD45.2^+^ cells and \>1% tdTomato^+^ among CD45.2^+^ cells.\
(F--I) Frequency of tdTomato^+^ cells among live CD45.2^+^ peripheral blood (F) T cells, (G) B cells, (H) monocytes, and (I) neutrophils in primary recipients at 16 weeks post-transplantation. For each lineage, only recipients exhibiting \>1% CD45.2^+^ cells within that lineage are shown. Individual data points are shown overlaid with mean ± SD. n = 6--8 primary recipients per group.\
(J) Percentage of tdTomato^+^ HSCs among CD45.2+ HSCs in primary recipients at 6 months post-transplantation Individual data points are shown overlaid with mean ± SD. n = 6--8 primary recipients per group.\
vg, viral genomes; Anc80, Anc80L65.\
See also [Figures S3](#SD1){ref-type="supplementary-material"}--[S6](#SD1){ref-type="supplementary-material"} and [Tables S1](#SD1){ref-type="supplementary-material"} and [S2](#SD1){ref-type="supplementary-material"}.](nihms-1527710-f0004){#F3}

![AAV-Transduced Hematopoietic Stem Cells Exhibit Long-Term Reconstitution Potential following Secondary Transplantation\
(A) Percentage of donor chimerism among live peripheral blood cells in secondary recipients at monthly intervals post-transplantation. Data points represent mean ± SD. n = 6--9 secondary recipients per group.\
(B) Frequency of secondary recipients with tdTomato^+^ multilineage engraftment within indicated peripheral blood lineages at 16 weeks post-transplant. tdTomato^+^ engraftment was determined using the same criteria as in [Figure 3E](#F3){ref-type="fig"}.\
(C--F) Frequency of tdTomato^+^ cells among live CD45.2^+^ peripheral blood (C) T cells, (D) B cells, (E) monocytes, and (F) neutrophils in secondary recipients at 16 weeks post-transplantation. For each lineage, only recipients exhibiting \>1% CD45.2^+^ cells within that lineage are shown. Individual data points are shown overlaid with mean ± SD. n = 6--9 mice per group.\
(G) Percentage of tdTomato^+^ HSCs among CD45.2^+^ HSCs in secondary recipients at 4--5 months post-transplantation. Individual data points are shown overlaid with mean ± SD. n = 6--9 secondary recipients per group.\
vg, viral genomes; Anc80, Anc80L65.\
See also [Figures S5](#SD1){ref-type="supplementary-material"} and [S6](#SD1){ref-type="supplementary-material"} and [Table S1](#SD1){ref-type="supplementary-material"}.](nihms-1527710-f0005){#F4}

###### 

KEY RESOURCES TABLE

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  REAGENT or RESOURCE                                                     SOURCE                                 IDENTIFIER
  ----------------------------------------------------------------------- -------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------
  Antibodies                                                                                                     

  Armenian Hamster Anti-Mouse CD3e ePluor® 450                            Thermo Fisher Scientific               Cat \#48-0031-80; RRID: AB_10733280

  Rat Anti-Human/Mouse CD45R (B220) eFluor® 450                           Thermo Fisher Scientific               Cat \#48-0452-80; RRID: AB_1548763

  Rat Anti-Mouse TER-119 eFluor® 450                                      Thermo Fisher Scientific               Cat \#48-5921-80; RRID: AB_1518809

  Rat Anti-Mouse Ly-6G/Ly-6C (Gr-1) eFluor® 450                           Thermo Fisher Scientific               Cat \#48-5931-82; RRID: AB_1548788

  Rat Anti-Mouse/Human CD11b APC-Cy7                                      Biolegend                              Cat\#101226; RRID: AB_830642

  Rat Anti-Mouse Ly-6A/E (Sca-1) PE-Cy7                                   Biolegend                              Cat\#108114; RRID: AB_493596

  Rat Anti-Mouse CD117 (c-Kit) APC                                        BD Biosciences                         Cat \#553356; RRID: AB_398536

  Armenian Hamster Anti-Mouse CD48 PITC                                   Biolegend                              Cat\#103404; RRID: AB_313019

  Rat Anti-Mouse CD150 (SLAM) Brilliant Violet 510                        Biolegend                              Cat\#115929; RRID: AB_2562189

  Rat Anti-Mouse CD16/CD32 (Mouse BD PC Block)                            BD Biosciences                         Cat \#553142; RRID: AB_394657

  Rat Anti-Mouse CD3 antibody PE-Cy7                                      Biolegend                              Cat\#100220; RRID: AB_1732057

  Rat Anti-Human/Mouse CD45R (B220) PITC                                  Thermo Fisher Scientific               Cat \#11-0452-85; RRID: AB_465055

  Rat Anti-Mouse Ly-6G/Ly-6C (Gr-1)Biotin                                 Biolegend                              Cat \#108404; RRID: AB_313369

  Mouse Anti-Mouse CD45.1 Pacific Blue                                    Biolegend                              Cat \#110722; RRID: AB_492866

  Mouse Anti-Mouse CD45.2 APC                                             Biolegend                              Cat\#109814; RRID: AB_389211

  Rat Anti-Mouse Lineage Cocktail Pacific Blue                            Biolegend                              Cat\#133310; RRID: AB_11150779

  Mouse Anti-Mouse CD45.2 Alexa Fluor® 700                                Biolegend                              Cat \#109822; RRID: AB_493731

  Rat Anti-Mouse TER-119 APC                                              Biolegend                              Cat\#116212; RRID: AB_313713

  Rat Anti-Mouse CD71 PITC                                                BD Biosciences                         Cat \#553266; RRID: AB_394743

  Armenian Hamster Anti-Mouse CD3e Biotin                                 Biolegend                              Cat\#100304; RRID: AB_312669

  Rat Anti-Human/Mouse CD45R (B220) Biotin                                Thermo Fisher Scientific               Cat \#13-0452-82; RRID: AB_466449

  Rat Anti-Mouse CD19 Biotin                                              Biolegend                              Cat \#115504; RRID: AB_313639

  Rat Anti-Mouse TER-119 Biotin                                           Biolegend                              Cat\#116204; RRID: AB_313705

  Rat Anti-Mouse Ly-6G/Ly-6C (Gr-1)Biotin                                 Biolegend                              Cat \#108404; RRID: AB_313369

  eBioscience Streptavidin ePluor450                                      Thermo Fisher Scientific               Cat \#48-4317-82; RRID: AB_10359737

  Rat Anti-Mouse CD34 PITC                                                Thermo Fisher Scientific               Cat \#11-0341-85; RRID: AB_465022

  Rat Anti-Mouse CD16/CD32 Alexa Fluor® 700                               Thermo Fisher Scientific               Cat \#56-0161-82; RRID: AB_493994

  Rat Anti-Mouse/Human CD11b APC                                          Biolegend                              Cat\#101212; RRID: AB_312795

  Rat Anti-Mouse Ly-6G Pacific Blue                                       Biolegend                              Cat\#127612; RRID: AB_2251161

  Rat Anti-Mouse Ly-6A/E (Sca-1) APC                                      Biolegend                              Cat\#108112; RRID: AB_313349

  Rat Anti-Mouse CD45 APC-Cy7                                             BD Biosciences                         Cat \#557659; RRID: AB_396774

  Rat Anti-Mouse CD11b APC-Cy7                                            BD Biosciences                         Cat \#557657; RRID: AB_396772

  Rat Anti-Mouse Ter-119 APC-Cy7                                          Biolegend                              Cat\#116223; RRID: AB_2137788

  Rat Anti-Mouse Ly-6A/E (Sca-1) APC                                      Thermo Fisher Scientific               Cat \#17-5981-82; RRID: AB_469487

  Hamster Anti-Mouse/Rat CD29 (β1-integrin) PITC                          Biolegend                              Cat\#102206; RRID: AB_312883

  Rat Anti-Mouse CD184 (CXCR4) Biotin                                     BD Biosciences                         Cat \#551968; RRID: AB_394307

  Anti-Myosin (Skeletal, Past) antibody                                   Millipore Sigma                        Cat \#M4276; RRID: AB_477190

  Anti-Myosin (Skeletal, Slow) antibody                                   Millipore Sigma                        Cat \#M8421; RRID: AB_477248

  Mouse Anti-Pax7 antibody                                                Developmental Studies Hybridoma Bank   Cat \#AB_528428; RRID: AB_528428

  Rabbit Anti-Laminin antibody                                            Millipore Sigma                        Cat \#AB2034; RRID: AB_91209

  Goat Anti-mouse IgG1, Alexa Fluor 488                                   Thermo Fisher Scientific               Cat \#A-21121; RRID: AB_2535764

  Goat Anti-rabbit IgG (H+L), Alexa Fluor 647                             Thermo Fisher Scientific               Cat \#A-21244; RRID: AB_2535812

  Mouse on Mouse (M.O.M.™) Basic Kit                                      Vector Laboratories                    Cat \#BMK-2202; RRID: AB_2336833

  Streptavidin-PE-Cy7                                                     BD Biosciences                         Cat \#557598; RRID: AB_I0049577

  CD45-ePluor450                                                          Thermo Fisher Scientific               Cat \#48-0451-82; RRID: AB_1518806

  CD140a (PDGPRa) -biotin                                                 Thermo Fisher Scientific               Cat \#13-1401-82; RRID: AB_466607

  CD24-PITC                                                               Thermo Fisher Scientific               Cat \#11-0242-82; RRID: AB_464988

  Sca-1-PerCP-Cy5.5                                                       Thermo Fisher Scientific               Cat \#45-5981-82; RRID: AB_914372

  Goat anti-mouse CD140a (PDGPRa)                                         R&D systems                            Cat \#AP1062-SP; RRID: AB_2236897

  Rabbit anti-RPP                                                         Rockland                               Cat \#600-401-379; RRID: AB_2209751

  Alexa Fluor 488 Affinipure Donkey anti-goat IgG                         Jackson Immunoresearch                 Cat \#705-545-147; RRID: AB_2336933

  Cy ™ 3 Affinipure Donkey anti-rabbit IgG                                Jackson Immunoresearch                 Cat \#711-165-152; RRID: AB_2307443

  4',6-diamino-2-phenyNndole (DAPI)                                       Thermo Fisher Scientific               Cat \#D1306; RRID: AB_2629482

  SYTOX Blue Dead Cell Stain, for flow cytometry                          Thermo Fisher Scientific               Cat \#S34857

  7-AAD                                                                   BD Biosciences                         Cat \#559925

  Streptavidin, Pacific Orange conjugate                                  Thermo Fisher Scientific               Cat \#S32365

  Anti-APC Microbeads                                                     Miltenyi Biotec                        Cat\#120-001-265

  Wheat Germ Agglutinin, Alexa Fluor 488 Conjugate                        Thermo Fisher Scientific               Cat\#W11261

  Propidium Iodide                                                        Millipore Sigma                        Cat\#P4170-25MG

  Calcein Blue, AM                                                        Thermo Fisher Scientific               Cat\#C1429

  eBioscience™ Streptavidin-APC                                           Thermo Fisher Scientific               Cat\#17-4317-82

  Bacterial and Virus Strains                                                                                    

  ElectroMAX™ Stbl4™ Competent Cells                                      Thermo Fisher Scientific               Cat\#11635018

  Chemicals, Peptides, and Recombinant Proteins                                                                  

  HBSS, calcium, magnesium, no phenol red                                 Thermo Fisher Scientific               Cat\#14025-134

  PBS (for cell culture)                                                  GE Healthcare (Hyclone)                Cat\#SH30071.03

  PBS (for staining media)                                                Millipore Sigma                        Cat\#P6178-500mL

  Dulbecco's Phosphate-Buffered Saline (DPBS), no calcium, no magnesium   Thermo Fisher Scientific               Cat\#14190-250

  Collagen I Rat Protein                                                  Thermo Fisher Scientific               Cat\#A1048301

  Natural Mouse Laminin, 1mg                                              Thermo Fisher Scientific               Cat\#23017015

  PGP-Basic, recombinant                                                  Millipore Sigma                        Cat \#P0291

  DMEM, high glucose                                                      Thermo Fisher Scientific               Cat\#11965118

  Ham's P10 Nutrient Mix, 500ml bottle                                    Thermo Fisher Scientific               Cat\#11550043

  Donor Horse Serum                                                       Atlanta Biologicals                    Cat\#S12150

  Penicillin-Streptomycin                                                 Thermo Fisher Scientific               Cat\#15140122

  GlutaMAX Supplement                                                     Thermo Fisher Scientific               Cat\#35050061

  Dexamethasone                                                           Millipore Sigma                        Cat\#D1756

  Insulin solution from bovine pancreas                                   Millipore Sigma                        Cat\#I0516

  Rosiglitazone                                                           Cayman Chemical                        Cat\#71740

  3-isobutyl-1-methylxanthine                                             Millipore Sigma                        Cat \#I5879

  Paraformaldehyde, 32% solution                                          VWR                                    Cat\#100496-496

  Triton X-100                                                            Millipore Sigma                        Cat \#T9284

  Triton X-100                                                            Thermo Fisher Scientific               Cat\#BP151

  Normal Goat Serum, Jackson Immuno                                       VWR                                    Cat\#102643-594

  Donkey Serum                                                            Millipore Sigma                        Cat \#D9663

  Bovine Serum Albumin (BSA)                                              Millipore Sigma                        Cat \#A9647

  Bovine Serum Albumin (BSA)                                              Millipore Sigma                        Cat \#A7030

  Gelatin from cold water fish skin                                       Millipore Sigma                        Cat \#G7765

  Tween 20                                                                Millipore Sigma                        Cat \#P1379

  BODIPY™ 493/503                                                         Thermo Fisher Scientific               Cat \#D3922

  Hoechst 33342, Trihydrochloride, Trihydrate                             Thermo Fisher Scientific               Cat \#H1399

  Cardiotoxin gamma from Naja pallida                                     Latoxin                                Cat \#L8102

  EDTA (0.5M), pH 8.0                                                     Thermo Fisher Scientific               Cat \#AM9261

  Dextran                                                                 Millipore Sigma                        Cat \#31392

  ACK Lysing Buffer                                                       Thermo Fisher Scientific               Cat \#A1049201

  Iodixanol                                                               Axis-Shield PoC AS                     Cat \#AXS-1114542-5

  Trizol LS                                                               Thermo Fisher Scientific               Cat \#1029610

  Isopentane (2-Methylbutane)                                             Millipore Sigma                        Cat \#M32631

  Paraformaldehyde (PPA), 32% solution, EM grade                          VWR                                    Cat \#100496-496

  Vectashield HardSet Antifade Mounting Medium with DAPI                  Vector Laboratories                    Cat \#H-1200

  Critical Commercial Assays                                                                                     

  SuperScript IV VILO Master Mix with ezDNase Enzyme                      Thermo Fisher Scientific               Cat \#11766050

  *Pax7* TaqMan assay                                                     Thermo Fisher Scientific               Mm01354484_m1

  *Myf5* TaqMan assay                                                     Thermo Fisher Scientific               Mm00435125_m1

  *Myod1* TaqMan assay                                                    Thermo Fisher Scientific               Mm00440387_m1

  *Myog* TaqMan assay                                                     Thermo Fisher Scientific               Mm00446194_m1

  *Gapdh* TaqMan assay                                                    Thermo Fisher Scientific               Mm99999915_g1

  TaqMan Past Advanced Master Mix                                         Thermo Fisher Scientific               Cat \#4444557

  Experimental Models: Cell Lines                                                                                

  HEK293                                                                  ATCC                                   Cat \#CRL-1573; RRID: CVCL_0045

  Experimental Models: Organisms/Strains                                                                         

  Mouse: C57B/10ScSn-Dmd^*mdx*^/J                                         The Jackson Laboratory                 JAX: 001801; RRID: IMSR_JAX:001801

  Mouse: B6;129S6-*Gt(ROSA)26Sortm9 (CAG-tdTomato)Hze*/J                  The Jackson Laboratory                 JAX: 007905; RRID: IMSR_JAX:007905

  Mouse: B6.Cg-Tg(Pax7-ZsGreen)1Kyba/J                                    The Jackson Laboratory                 JAX: 029549; RRID: IMSR_JAX:029549

  Mouse: B6.SJL-*Ptprc^a^ Pepc^b^*/BoyJ                                   The Jackson Laboratory                 JAX: 002014; RRID: IMSR_JAX:002014

  Mouse: C57BL/6J                                                         The Jackson Laboratory                 JAX: 000664; RRID: IMSR_JAX:000664

  Oligonucleotides                                                                                               

  *Pax7_zsGreen*\_F; CTGCATGTACCACGAGTCCA                                                                        N/A

  *Pax7_zsGreen*\_R; GTCAGGTGCCACTTCTGGTT                                                                        N/A

  tdTomato_WT_F; AAGGGAGCTGCAGTGGAGTA                                                                            N/A

  tdTomato_WT_R; CCGAAAATCTGTGGGAAGTC                                                                            N/A

  tdTomato_Knock-in_F; CTGTTCCTGTACGGCATGG                                                                       N/A

  tdTomato_Knock-in_R; GGCATTAAAGCAGCGTATCC                                                                      N/A

  Recombinant DNA                                                                                                

  Package plasmid (pAAV2/Anc80) L65AAP)                                   Addgene                                Cat \#92307

  Transgene plasmid (pAAV Cre)                                            GTVC                                   In house production

  pAAV-Cre control plasmid                                                Cell Biolabs                           AAV-401

  Helper plasmid (ΔP6)                                                    GTVC                                   In house production

  Package plasmid (pKAAV2/8, pKAAV2/9)                                    GTVC                                   In house production

  REAGENT or RESOURCE                                                     SOURCE                                 IDENTIFIER

  Software and Algorithms                                                                                        

  BD PACSDiva™ Software v8.0.2                                            BD Biosciences                         <http://www.bdbiosciences.com/us/instruments/research/software/flow-cytometry-acquisition/bd-facsdiva-software/m/111112/overview> ;\
                                                                                                                 RRID: SCR_001456

  FlowJo v10.1r5                                                          FlowJo                                 <https://www.flowjo.com/solutions/flowjo>;\
                                                                                                                 RRID: SCR_008520

  Other                                                                                                          

  Covidien Monoject Softpack Insulin Syringe, 1/2mL, 28Gx 1/2"            Covidien                               1188528012

  Equisul-SDT® (Sulfadiazine Trimethoprim)                                Aurora Pharmaceutical                  Cat \#28002

  Irradiated PicoLab Mouse Diet 20 5058                                   LabDiet, St. Louis, MO                 Cat \#0007689

  Irradiated LabDiet Prolab Isopro RMH 3000 5P75                          LabDiet, St. Louis, MO                 Cat \#0006972

  Tissue-Tek® O.C.T. Compound, Sakura® Pinetek                            VWR                                    25608-930
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Highlights

-   Multiple AAV serotypes transduce tissue stem cells via systemic or local delivery

-   AAV-delivered Cre recombinase modifies stem cells in multiple anatomical niches

-   *In vivo* AAV transduction does not require stem cell isolation or transplantation

-   AAV-transduced stem cells retain differentiation and engraftment capacities
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